Both InVivoPlexTM –TUMOR Kits can be used for tumor localized delivery of plasmid DNA, siRNA or a combination of the two, as shown in the figure below. A pair of Optimize Kits may be used with reporter gene plasmid combined with a pair of siRNA oligonucleotides, one negative and the other matching the reporter gene, as shown in the figure. The Efficacy Kit is designed for studies with multiple treatment groups for gene function and tumor growth inhibition. The Efficacy Kit provides four nanoparticle reagent vials for studies with negative and positive control, and multiple experimental nucleic acid agents, or for multiple administrations of a nucleic acid agent, both usually needed to obtain convincing results showing an effect on tumor growth by nucleic acid mediated gene inhibition or expression. This kit provides four vials of nanoparticle reagent for studies with multiple groups, such as negative control, positive control, and multiple experimental agents.
Tumor siRNA activity by co-delivery with plasmid. Mice bearing U87 tumors were treated i.v. with InVivoPlex™ –TUMOR with 40 ug pCI-Luc plasmid (yellow) versus 40 ug pCI-Luc plus 20 ug Qiagen All-Star negative control siRNA (green) or 20 ug anti-Luc siRNA (red). n=8
To learn more about InVivoPlex™ –TUMOR regarding tumor selectivity go to Vascular Tumor Localized Nucleic Acid Activity, or more about murine safety go to Excellent Safety.
To place an order, call 1-888-770-2101 or go to Order.